Results for
""Ifosfamide""[mesh_terms]

Prevention of ifosfamide nephrotoxicity by N-acetylcysteine: clinical pharmacokinetic considerations.

Nancy Chen, Katarina Aleksa, Cindy Woodland, Michael Rieder, Gideon Koren

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 2007;14(2):e246-50

Ifosfamide-induced nephrotoxicity in oncological patients.

Julia Cristina Coronado-Arroyo, Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vásquez, Luis Alberto Concepción-Urteaga, Marcio José Concepción-Zavaleta, Freddy Shanner Chávez-Vásquez, Alexandra Noelia Rodríguez-Angulo, Sonia Elizabeth Gonzáles-Saldaña, Carlos César Alcalde-Loyola, Francisca Elena Zavaleta-Gutiérrez, Juan Carlos Haro-Varas

Expert review of anticancer therapy 2024;24(1-2):5-14

Ifosfamide encephalopathy: a case report.

Michele Pavarana, Rolando Nortilli, Francesca Valcamonico, Silvia Romito, Tiziano Zanoni, Gianluigi Cetto

Tumori 2005;91(2):197-200

Conventional Chemotherapy Nephrotoxicity.

Shruti Gupta, Ignacio Portales-Castillo, Amir Daher, Abhijat Kitchlu

Advances in chronic kidney disease 2022;28(5):402-414.e1

Glufosfamide: beta-D-Glc-IPM, D 19575.

Drugs in R&D 2005;6(1):49-52

Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature.

Steven N Luminais, Xiao T Chen, Darwin Roman, Brian Ma, Alexander B Christ, James S Hu

Journal of medical case reports 2022;16(1):252

The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.

J T Hartmann, S Knop, L M Fels, A van Vangerow, H Stolte, L Kanz, C Bokemeyer

Anti-cancer drugs 2000;11(1):1-6

Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention.

Nancy Chen, Gideon Koren, Michael Rieder, Lauren Hanly

Expert opinion on drug safety 2009;8(2):155-68

A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.

L M Fels, S Knop, L Kanz, C Bokemeyer, J T Hartmann, H Stolt

Investigational new drugs 2000;18(3):281-9

Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.

S Leyvraz, M Zweifel, G Jundt, A Lissoni, T Cerny, C Sessa, M Fey, D Dietrich, H P Honegger

Annals of oncology : official journal of the European Society for Medical Oncology 2006;17(4):646-51

Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study.

B Kasper, I Scharrenbroich, T Schmitt, P Wuchter, S Dietrich, A D Ho, G Egerer

Bone marrow transplantation 2010;45(7):1234-8

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

Darren R Feldman, James Hu, Tanya B Dorff, Kristina Lim, Sujata Patil, Kaitlin M Woo, Maryann Carousso, Amanda Hughes, Joel Sheinfeld, Manjit Bains, Siamak Daneshmand, Charlene Ketchens, Dean F Bajorin, George J Bosl, David I Quinn, Robert J Motzer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017;34(21):2478-83

Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.

M Fouladi, D Stempak, J Gammon, J Klein, R Grant, M L Greenberg, G Koren, S Baruchel

Cancer 2001;92(4):914-23

Central neurocytoma responsive to topotecan, ifosfamide, carboplatin.

Elham Amini, Tina Roffidal, Alice Lee, Gregory N Fuller, Anita Mahajan, Leena Ketonen, Nathan Kobrinsky, Mitchell S Cairo, Robert J Wells, Johannes E A Wolff

Pediatric blood & cancer 2008;51(1):137-40

Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study.

M Nardi, S De Marco, A Fabi, A Aloe, E Magnani, P Grandinetti, F Cognetti

Cancer chemotherapy and pharmacology 2000;45(6):513-5